Finance

Pharmaceutical production
Pharmalot

Sun Pharma faces a new problem as Indian regulator probes whistleblower charges

By Ed Silverman

Cambridgeport
Exclusive

New documents shed light on secretive ElevateBio, next step for former Alexion execs

By Kate Sheridan

Superbug Q And A
First Opinion

What’s holding pharma back from the next antibiotic breakthrough?

By Peter Bak

PhRMA & congress
Politics

The drug industry is headed back to Congress to make its case. Will Democrats keep the door open?

By Nicholas Florko

Four mini-pig piglets stand around
Health

A nonprofit biotech venture is betting on pig skin to help burn victims with first-ever clinical trial

By Kate Sheridan

The Readout LOUD

LISTEN: Using the word ‘cure,’ an FDA loophole, & making biotech history

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Donald Trump & Xi Jinping
Politics

The Trump administration called this biotech VC firm a suspicious agent of China. It’s run by U.S. citizens

By Rebecca Robbins

Charles Grassley
Politics

With new drug pricing legislation, Grassley and Wyden hint at the next steps for a powerful Senate committee

By Ike Swetlitz

Pharmalot

Pharmalittle: Insys pivots from opioids to cannabis-derived drugs; Republicans oppose Trump Medicare price plan

By Ed Silverman

Glaxo Smith Kline
Pharmalot

What does Glaxo get with its Tesaro deal? Here’s what the wags are saying

By Ed Silverman

Pharmalot

Pharmalittle: Glaxo buys Tesaro for $5.1 billion; showdown as Takeda deal for Shire nears

By Ed Silverman

Taxes Health Care Q&A
Pharmalot

Big drug makers are socking away more cash lately thanks to the tax overhaul, and it’s likely to be used for more deals

By Ed Silverman

Pharmalot

Pharmalittle: Will a judge nix the CVS-Aetna deal? Takeda to sell billions in assets to pay for Shire

By Ed Silverman

White pills on yellow background
Politics

A drug pricing duel: Tying U.S. drug prices to what other countries pay

By Elizabeth Cooney

MassNextGen
Biotech

Almost no venture capital funding goes to women. Can a pitchfest bring parity to biotech?

By Kate Sheridan

Pharmalot

Pharmalittle: Former Takeda chairman opposes Shire deal; FDA says intensity and duration of shortages is spiking

By Ed Silverman

Pharmalot

Pharmalittle: Trump team proposes some Medicare changes; Bristol-Myers cancer drug fails another trial

By Ed Silverman

China flags
Biotech

Trump administration accuses China of unfairly using venture capital to acquire American biotech

By Rebecca Robbins

Aveo Pharmaceuticals
Biotech

Jury finds former Aveo CFO misled investors about kidney cancer drug

By Jonathan Saltzman — Boston Globe

Malaria - South Sudan
Pharmalot

Only a few drug makers are actively targeting medicines needed in poor countries

By Ed Silverman

Doctors Seek Higher Fees From Health Insurers
First Opinion

6 lessons from the fight to reform how primary care physicians are paid

By Andrew M. Snyder

Mail bag
Pharmalot

You have questions on biosimilars. We have answers

By Nicholas Florko and Ed Silverman

Pharmalot

Pharmalittle: AstraZeneca immunotherapy trial flops; Takeda shareholders trying to block Shire deal

By Ed Silverman

Lessons Learned
Lessons Learned

Lessons Learned: How to balance residency and a budding career in venture capital

By Kate Sheridan

The Readout LOUD

LISTEN: The biggest-ever IPO, drug prices rising in tandem, and burner Twitter accounts

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Brigham - Dr. Elizabeth Nabel
Hospitals

Covering the cost of high-priced therapies like CAR-T is ‘not sustainable,’ hospital chief says

By Andrew Joseph

Ketogenic diet
Business

A startup for diabetes patients rolls out a new model: Insurers only pay if the service works

By Rebecca Robbins

Pharmalot

Pharmalittle: Lawmakers pressed on drug-cost pledges; Walmart and Home Depot embrace co-pay accumulators

By Ed Silverman

Social media and pharma illo
Business

As social media ‘influencers,’ patients are getting a voice. And pharma is ready to pay up

By Kate Sheridan

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy